Pacific Biosciences Of California (PACB) Capital Expenditures Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 9.52% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | -11.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.82% |
| Mar 31, 2026 | -6.49% |
| Dec 31, 2025 | -44.00% |
| Sep 30, 2025 | -26.42% |
| Jun 30, 2025 | -48.47% |
| Mar 31, 2025 | -27.45% |
| Dec 31, 2024 | -17.14% |
| Jun 30, 2024 | -1.95% |
| Mar 31, 2024 | 113.07% |
| Dec 31, 2023 | 211.44% |
| Sep 30, 2023 | 15.69% |
| Jun 30, 2023 | 92.29% |
| Mar 31, 2023 | 216.83% |
| Dec 31, 2022 | 226.42% |
| Sep 30, 2022 | 71.60% |
| Jun 30, 2022 | 87.16% |
| Mar 31, 2022 | 42.66% |
| Dec 31, 2021 | 265.93% |
| Jun 30, 2021 | 4.98% |
| Mar 31, 2021 | 5.24% |